{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:01:03Z","timestamp":1783026063931,"version":"3.54.6"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["Hi 399\/6-1"],"award-info":[{"award-number":["Hi 399\/6-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.neuropharm.2013.04.062","type":"journal-article","created":{"date-parts":[[2013,8,29]],"date-time":"2013-08-29T09:30:32Z","timestamp":1377768632000},"page":"152-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Evaluation of P-glycoprotein (abcb1a\/b) modulation of [18F]fallypride in MicroPET imaging studies"],"prefix":"10.1016","volume":"84","author":[{"given":"Markus","family":"Piel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bausbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Georg","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"R\u00f6sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2013.04.062_bib1","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1126\/science.1168750","article-title":"Structure of p-glycoprotein reveals a molecular basis for poly-specific drug binding","volume":"323","author":"Aller","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2013.04.062_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0893-133X(02)00287-7","article-title":"Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs","volume":"27","author":"Andersson","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.04.062_bib3","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00702-008-0030-y","article-title":"Decreased blood\u2013brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA","volume":"115","author":"Bartels","year":"2008","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpsychires.2006.10.002","article-title":"Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients","volume":"42","author":"Bozina","year":"2008","journal-title":"J.\u00a0Psych. Res."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2174\/156802610792928022","article-title":"Substrates, inhibitors and activators of p-glycoprotein: candidates for radiolabeling and imaging perspectives","volume":"10","author":"Colabufo","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib6","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/syn.20904","article-title":"Striatal and extrastriatal MicroPET imaging of D2\/D3 dopamine receptors in rat brain with [18F]Fallypride and [18F]Desmethoxyfallypride","volume":"65","author":"Constantinescu","year":"2011","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2013.04.062_bib7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1073\/pnas.86.2.695","article-title":"Multidrug\u2013resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites","volume":"86","author":"Cordon-Cardo","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib8","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1128\/MCB.10.4.1652","article-title":"Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities","volume":"10","author":"Devault","year":"1990","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/dmd.109.027011","article-title":"Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function","volume":"37","author":"Dutheil","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s00406-006-0664-4","article-title":"ABC drug transporter at the blood-brain barrier \u2013 effects on drug metabolism and drug response","volume":"256","author":"Ebinger","year":"2006","journal-title":"Eur. Arch. Psy. Clin. N."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1515\/DMDI.2006.21.3-4.139","article-title":"The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites","volume":"21","author":"Ejsing","year":"2006","journal-title":"Drug Metab. Drug Interact."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib12","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1211\/0022357043969","article-title":"Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds \u2013 implications for pharmacokinetics for selected substrates","volume":"56","author":"El Ela","year":"2004","journal-title":"J.\u00a0Pharm. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11307-005-0951-x","article-title":"Positron Emission Tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain","volume":"7","author":"Elsinga","year":"2005","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/dmd.107.017434","article-title":"In-vitro P-glycoprotein assays to predict the in\u00a0vivo interactions of P-glycoprotein with drugs in the central nervous system","volume":"36","author":"Feng","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib15","first-page":"543","article-title":"Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein","volume":"36","author":"Foxwell","year":"1989","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib16","first-page":"109","article-title":"Quantification of D2-like dopamine receptors in the human brain with 18F-Desmethoxyfallypride","volume":"44","author":"Gr\u00fcnder","year":"2003","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1006\/nimg.1997.0303","article-title":"Parametric imaging of ligand-receptor binding in PET using a simplified reference region model","volume":"6","author":"Gunn","year":"1997","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuropharm.2013.04.062_bib18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/pharmaceutics2020258","article-title":"Induction of drug transporters alters disposition of risperidone \u2013 a study in mice","volume":"2","author":"Holthoever","year":"2010","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neuropharm.2013.04.062_bib19","first-page":"81","article-title":"In\u00a0vivo evaluation of p-glycoprotein modulation of 8 PET radioligands used clinically","volume":"48","author":"Ishiwata","year":"2007","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib20","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00228-010-0850-1","article-title":"The role of CYP2D6 and ABCB1 pharmacogenetics in drug-na\u00efve patients with first-episode schizophrenia treated with risperidone","volume":"66","author":"Jovanovi\u0107","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A\u00a0surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2013.04.062_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/syn.20348","article-title":"Effect of a p-glycoprotein inhibitor, cyclosporin a, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(\u2014)-RWAY","volume":"61","author":"Liow","year":"2007","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2013.04.062_bib23","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","article-title":"Distribution volume ratios without blood sampling from graphical analysis of PET data","volume":"16","author":"Logan","year":"1996","journal-title":"J.\u00a0Cereb. Blood Flow Metab."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib24","first-page":"158","article-title":"Bioavailability assessment of cyclosporine in the rat. Influence of route administration","volume":"18","author":"Luke","year":"1990","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib25","doi-asserted-by":"crossref","first-page":"11901","DOI":"10.1021\/bi000559b","article-title":"Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis","volume":"39","author":"Martin","year":"2000","journal-title":"Biochem"},{"key":"10.1016\/j.neuropharm.2013.04.062_bib26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0969-8051(94)00117-3","article-title":"Fluorinated benzamide neuroleptics \u2013 III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide as an Improved Dopamine D-2 Receptor Tracer","volume":"22","author":"Mukherjee","year":"1995","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib27","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s11095-007-9374-5","article-title":"Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development","volume":"24","author":"Ohtsuki","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","article-title":"Blood-brain barrier delivery","volume":"12","author":"Pardridge","year":"2007","journal-title":"Drug Disc. Today"},{"key":"10.1016\/j.neuropharm.2013.04.062_bib29","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2007"},{"key":"10.1016\/j.neuropharm.2013.04.062_bib30","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1073\/pnas.94.8.4028","article-title":"Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins","volume":"94","author":"Schinkel","year":"1997","journal-title":"Prog. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-409X(98)00085-4","article-title":"P-Glycoprotein, a gatekeeper in the blood\u2013brain barrier","volume":"36","author":"Schinkel","year":"1999","journal-title":"Adv. Drug Del. Rev."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib32","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00702-005-0367-4","article-title":"Cyclosporine A (CsA) affects the pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)","volume":"113","author":"Schmitt","year":"2006","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib33","first-page":"964","article-title":"Parametric mapping of binding in human brain of d2 receptor ligands of different affinities","volume":"46","author":"Siessmeier","year":"2005","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib34","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum. Mol. Gen."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.110.079608","article-title":"Transport of selected PET radiotracers by human p-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in\u00a0vitro screening","volume":"52","author":"Tournier","year":"2011","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuron.2007.11.017","article-title":"Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression","volume":"57","author":"Uhr","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2013.04.062_bib37","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/jcbfm.2011.73","article-title":"The applicability of SRTM in [18F]fallypride PET investigations: impact of scan durations","volume":"31","author":"Vernaleken","year":"2011","journal-title":"J.\u00a0Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.neuropharm.2013.04.062_bib38","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/js980082d","article-title":"Role P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics","volume":"87","author":"Wacher","year":"1998","journal-title":"J.\u00a0Pharm. Sci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813003857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813003857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:37:26Z","timestamp":1588970246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390813003857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":38,"alternative-id":["S0028390813003857"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.04.062","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of P-glycoprotein (abcb1a\/b) modulation of [18F]fallypride in MicroPET imaging studies","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.04.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}